AB5112
Anti-Parkin Antibody, a.a. 305-323
serum, Chemicon®
Sinónimos:
Anti-AR-JP, Anti-LPRS2, Anti-PARK2, Anti-PDJ
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
biological source
rabbit
Quality Level
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
rat, human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... PARK2(5071)
Specificity
Parkin. Parkinson′s disease is a common neurodegenerative disease is caused by slow death of neurons in the substantial nigra, a brain region that utilizes the neurotransmitter dopamine. Parkin, a recently discovered gene encoding a large protein, may be involved in normal and abnormal protein degradation in cells. Recent evidence indicates that point mutations in the Parkin gene appear to be responsible for the pathogenesis of some forms of Parkinson′s disease.
Immunogen
A 19 amino acid peptide (RILGEEQYNRYQQYGAEEC) corresponding to amino acids 305-323 of the human parkin molecule. An internal peptide sequence was chosen to avoid the possibility of cross reactivity with ubiquitin.
Epitope: a.a. 305-323
Application
Detect Parkin using this Anti-Parkin Antibody, a.a. 305-323 validated for use in ELISA, WB, IH.
Immunohistochemistry: 1:1000 - 1:2000
One site ELISA
Western blot: 1:1000 - 1:2000 (recognizes a doublet at 44-52 kDa on blots of human brain)
The immunogen peptide is available (cat# AG237) for pre-absorbtion controls.
Optimal working dilutions must be determined by the end user.
One site ELISA
Western blot: 1:1000 - 1:2000 (recognizes a doublet at 44-52 kDa on blots of human brain)
The immunogen peptide is available (cat# AG237) for pre-absorbtion controls.
Optimal working dilutions must be determined by the end user.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Physical form
Rabbit serum. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove insoluble material. Contains no preservative.
Storage and Stability
Maintain lyophilized material at at -20°C to -70°C for up to 12 months after date of receipt. After reconstitution maintain at -20°C to -70°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles. Glycerol (ACS grade or better) can be added (1:1) for greater stability.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
V D'Agata et al.
The European journal of neuroscience, 12(10), 3583-3588 (2000-10-13)
A mutation in the parkin gene has been identified as the cause for an autosomal recessively inherited form of early onset Parkinson's disease. We have recently isolated the mRNA coding for the rat homologue of parkin and showed its widespread
Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance.
Lonskaya, I; Hebron, ML; Desforges, NM; Schachter, JB; Moussa, CE
Journal of Molecular Medicine null
Irina Lonskaya et al.
EMBO molecular medicine, 5(8), 1247-1262 (2013-06-06)
Tyrosine kinase inhibitors (TKIs) are effective therapies for leukaemia. Alzheimer is a neurodegenerative disease characterized by accumulation of β-amyloid (plaques) and hyper-phosphorylated Tau (tangles). Here we show that AD animals have high levels of insoluble parkin and decreased parkin-Beclin-1 interaction
Paola Lenzi et al.
International journal of molecular sciences, 22(10) (2021-06-03)
Glioblastoma (GBM) cells feature mitochondrial alterations, which are documented and quantified in the present study, by using ultrastructural morphometry. Mitochondrial impairment, which roughly occurs in half of the organelles, is shown to be related to mTOR overexpression and autophagy suppression.
Grazia Maugeri et al.
International journal of oncology, 47(4), 1282-1292 (2015-08-05)
Mutations of parkin gene are not restricted to familial forms of Parkinsonism but they also occur in a wide variety of malignancies including gliomas. Parkin over-expression reduces glioma cells proliferation and analysis of its expression is predictive for the survival
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico